Delayed administration of nafamostat mesylate inhibits thrombin-mediated blood–spinal cord barrier breakdown during acute spinal cord injury in rats

BACKGROUND: Nafamostat mesylate (nafamostat, NM) is an FDA-approved serine protease inhibitor that exerts anti-neuroinflammation and neuroprotective effects following rat spinal cord injury (SCI). However, clinical translation of nafamostat has been limited by an unclear administration time window a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chenxi, Zhou, Tiangang, Zhao, Xiaoqing, Pang, Yilin, Li, Wenxiang, Fan, Baoyou, Li, Ming, Liu, Xinjie, Ma, Lei, Zhang, Jiawei, Sun, Chao, Shen, Wenyuan, Kong, Xiaohong, Yao, Xue, Feng, Shiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287720/
https://www.ncbi.nlm.nih.gov/pubmed/35842640
http://dx.doi.org/10.1186/s12974-022-02531-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287720/
https://www.ncbi.nlm.nih.gov/pubmed/35842640
http://dx.doi.org/10.1186/s12974-022-02531-w

Ejemplares similares